Samsung Backs Alzheimer's Blood Test Developer C2N Diagnostics with $10M Investment

In a significant move for the pharmaceutical and diagnostic industries, Samsung has invested $10 million in C2N Diagnostics, a St. Louis-based company specializing in Alzheimer's disease blood tests. This investment, announced on March 13, 2025, aims to accelerate C2N's commercial operations and research and development efforts.

Samsung's Strategic Investment in Life Sciences

The investment comes from multiple Samsung entities, including Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation. Jaywoo Kim, Executive VP of Samsung C&T, emphasized the company's commitment to the life sciences sector, stating, "The investment into C2N Diagnostics shows Samsung's continued dedication to future growth in the Life Science sector by seeking new business opportunities based on intelligent analytics and uniquely special diagnostics technologies."

This move follows Samsung's previous investments in biologics CDMO and biosimilar businesses, demonstrating the conglomerate's expanding interest in healthcare and biotechnology.

C2N Diagnostics: Advancing Alzheimer's Blood Testing

C2N Diagnostics, a former Fierce Medtech Fierce 15 winner, has been making significant strides in Alzheimer's diagnostics. The company's PrecivityAD2 blood test recently received regulatory approval in the United Kingdom and has seen its first clinical uses in Canada as of late January 2025.

The PrecivityAD2 test, launched in 2023, utilizes mass spectrometry to detect minute quantities of tau and beta-amyloid proteins in the bloodstream, which are associated with brain amyloid plaques. This non-invasive test aims to provide a cost-effective and accessible method for assessing the likelihood of a positive or negative result in more invasive or expensive diagnostic procedures for Alzheimer's disease.

Growing Support for C2N's Innovative Approach

Samsung's investment is the latest in a series of financial endorsements for C2N Diagnostics. In March 2024, the company received a $15 million investment from Eisai, following the FDA approval of Eisai and Biogen's Alzheimer's therapy, Leqembi. Additionally, C2N has garnered support from other organizations:

• GHR Foundation provided $15 million for a development program targeting tau-based biomarkers.
• The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator initiative contributed over $7 million.

These investments highlight the growing interest in blood-based biomarkers for Alzheimer's disease and the potential impact of C2N's technology on early diagnosis and treatment strategies.